effect of green tea treatment on the glycation, antioxidant status and lipid profile in type 2 diabetic female patients

ABSTRACT

Amongst the numerous co-adjuvant therapies which could influence the incidence and progression of diabetic complications, antioxidants and flavonoids are currently being tested in several clinical trials. Green tea [GT], catechins, has been reported to possess a potent antioxidative properties, and preventive effects against various oxidative diseases. To evaluate the effect of short-term supplementation with GT and its benefit on decreasing the incidence of some of diabetic complications. The effect of GT tablets [Igm] which is equivalent to 200 mg catechin as a co-adjuvant therapy with the oral hypoglycemic drug in a group of 36 Type 2 diabetic female patients was investigated, using a randomized single-blind placebo controlled parallel design, for a period of three months. Parameters of glycation, oxidative stress, lipid profile and C-reactive protein were measured before and after the intervention. An approach to find a relationship between patients response to GT treatment and disease age [history]. GT supplementation resulted in a significantly decrease in serum fasting blood glucose, fructosamine, total-cholesterol and triglycerides by 22.40%, 8.5%, 36.53% and 42.17% respectively, in diabetic patients under this intervention, with a non significant change in HbAlc and C-reactive protein. It also increased blood GSH and serum NO level by 15.16% and 21.5% respectively with a marked decrease in serum MDA level by 43.47% in diabetic patients under this intervention. Moreover, A direct relationship was found between disease' age and patients' high response to GT administration. GT co-administration with the oral hypoglycemic drug proved to improve patients antioxidants status, lipid profile and to a little extent the glucose levels and consequently decreasing the extent and time of occurrence of diabetic complications. Recommendation of GT administration, as a natural product in diabetic female patients for a specified dosage schedule might improve patients' health and quality of life